Cell therapy (CAR-T) · Kills target cells, directed at CD20 (MS4A1) · developed by Mustang Bio
MB-106 is an autologous CAR-T cell therapy engineered with a lentiviral vector to express a chimeric antigen receptor targeting CD20, a B-cell surface antigen. The CAR incorporates CD28 and 4-1BB co-stimulatory domains and the CD3 zeta signaling chain. It is being studied in relapsed or refractory B-cell malignancies including lymphomas, leukemias, and related disorders.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05360238 | Phase 1/2 | Follicular B-cell Non-Hodgkin's Lymphoma | Terminated | MBIO |
| NCT05645744 | N/A | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Terminated | MBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell Lymphoma RefractoryBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Lymphocytic Leukemia in RelapseChronic Lymphoid Leukemia in RelapseDiffuse Large B Cell LymphomaFollicular B-cell Non-Hodgkin's LymphomaHairy Cell LeukemiaMantle Cell Lymphoma RecurrentMantle Cell Lymphoma RefractorySmall Lymphocytic Lymphoma, RelapsedWaldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia Refractory
Updated Oct 3, 2026. Something wrong or missing? Report it on the MBIO page.
See MBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MBIO catalysts and pipeline →